Cytokinetics (CYTK) Cash & Equivalents (2016 - 2024)
Historic Cash & Equivalents for Cytokinetics (CYTK) over the last 16 years, with Q3 2024 value amounting to $47.3 million.
- Cytokinetics' Cash & Equivalents fell 5276.86% to $47.3 million in Q3 2024 from the same period last year, while for Sep 2024 it was $47.3 million, marking a year-over-year decrease of 5276.86%. This contributed to the annual value of $113.4 million for FY2023, which is 6879.37% up from last year.
- Per Cytokinetics' latest filing, its Cash & Equivalents stood at $47.3 million for Q3 2024, which was down 5276.86% from $190.5 million recorded in Q2 2024.
- Cytokinetics' 5-year Cash & Equivalents high stood at $200.8 million for Q3 2020, and its period low was $37.2 million during Q2 2021.
- In the last 5 years, Cytokinetics' Cash & Equivalents had a median value of $93.6 million in 2022 and averaged $95.1 million.
- Per our database at Business Quant, Cytokinetics' Cash & Equivalents surged by 40666.6% in 2020 and then plummeted by 5490.21% in 2021.
- Cytokinetics' Cash & Equivalents (Quarter) stood at $83.0 million in 2020, then soared by 35.77% to $112.7 million in 2021, then crashed by 40.37% to $67.2 million in 2022, then soared by 68.79% to $113.4 million in 2023, then plummeted by 58.32% to $47.3 million in 2024.
- Its Cash & Equivalents stands at $47.3 million for Q3 2024, versus $190.5 million for Q2 2024 and $120.4 million for Q1 2024.